Sanofi Weighs Takeover of Insmed, Sending Shares Up More Than 18%
SentiSense · Published · Updated
Sanofi is studying a potential acquisition of Insmed, Bloomberg News reported on November 19, citing people familiar with the matter. Insmed shares jumped more than 18% and were briefly halted for volatility, while call option volume ran well above normal. No price or terms were reported, Sanofi said it does not comment on market rumors, and any deal could still be weeks away.
SNY is weighing an acquisition of INSM, Bloomberg News reported on Thursday, November 19, citing people familiar with the matter. According to the report, as carried by Reuters via Investing.com, the French drugmaker is speaking with advisers as it studies a potential deal, deliberations are ongoing, and any transaction could still be weeks away. Sanofi said it does not comment on market rumors. Bloomberg framed the interest as part of Sanofi's hunt for its next blockbuster treatment under a new CEO.
Insmed shares reacted immediately. They surged more than 18% and were temporarily halted by a volatility circuit breaker, and our own delayed quote showed the stock at $141.77, up 18.3%, at 1:19 PM ET. Options traders piled in as well: 7,564 Insmed call options changed hands by late morning, roughly 85% above the typical 4,092 contracts, as shares traded as high as $138.24 at that point. Before the report, Insmed carried a market value of about $26.3 billion according to LSEG data, after falling about 40% over the preceding 12 months, against Sanofi's market value of about $111.3 billion.
The strategic logic centres on Brinsupri, Insmed's bronchiectasis drug. At the Jefferies healthcare conference on November 17, CEO Will Lewis said Brinsupri could reach at least $7 billion in US peak sales, expected $1.35 billion to $1.4 billion in its first full launch year, and said Insmed expects to become cash-flow positive next year. Insmed also has a US regulatory decision on frontline use of ARIKAYCE expected at the end of January. Its most recent quarter, reported October 29, showed revenue of $524.43 million, up 268.4% year over year and ahead of the $500.36 million estimate, alongside a loss of $0.46 per share against a $0.38 consensus loss.
What to watch: no price, premium or financing was disclosed, and the reports note there is no guarantee Sanofi's interest leads to an agreement, while other bidders could emerge. For Insmed holders, the key questions are whether a formal approach follows and at what premium to the pre-report price; for Sanofi, whether a deal of roughly a quarter of its own equity value can be justified by Brinsupri's growth runway.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis